marimastat has been researched along with Angiogenesis, Pathologic in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Anceschi, C; Chiarugi, P; Chillà, A; De Palma, G; Del Rosso, M; Del Rosso, T; Fibbi, G; Frediani, E; Laurenzana, A; Margheri, F; Pelagio, G; Scavone, F; Tufaro, A | 1 |
| He, W; Li, S; Lv, Y; Xiao, Q; Yin, L; Zhao, X; Zhu, L | 1 |
| Baryshnikov, A; Borovjagin, AV; Cobbs, C; Kaverina, N; Lin, B; Schroeder, B; Shah, N; Ulasov, I | 1 |
| Buchsbaum, DJ; McNally, LR; Rosenthal, EL; Skipper, JB; Wang, W | 1 |
| Bloys, H; Kaijzel, EL; Löwik, CW; Snoeks, TJ; van Beek, E; van Hinsbergh, VW; van Wijngaarden, J | 1 |
| Barrett, M; Burnitz, MC; Dipierro, C; Eto, M; Gibson, JJ; Myers, C; Phelps, C; Read, P; Somlyo, AP; Somlyo, AV | 1 |
| Augustin, HG | 1 |
| Fujii, M; Furukawa, T; Kameyama, K; Kimata, M; Kitajima, M; Kubota, T; Kumai, K; Minagawa, A; Okada, Y; Otani, Y; Saikawa, Y; Wada, N; Yoshida, M; Yoshimizu, N | 1 |
| Yamada, K; Yamaguchi, S; Yamamura, T | 1 |
| Blann, AD; Caine, GJ; Christodoulos, K; Harris, AL; Lip, GY | 1 |
| Takeshima, H | 1 |
| Takano, S | 1 |
| Kuwano, M; Ono, M | 2 |
| Dickson, RB; Hawkins, MJ; Wojtowicz-Praga, SM | 1 |
| Nelson, NJ | 1 |
| Bout, JC; Soncin, F; Vandenbunder, B | 1 |
| Ichikawa, Y; Ishikawa, T; Shimada, H; Tanaka, K; Togo, S | 1 |
8 review(s) available for marimastat and Angiogenesis, Pathologic
| Article | Year |
|---|---|
[Angiogenesis research--quo vadis?].
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Cell Communication; Drug Evaluation, Preclinical; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Inhibitors; Ephrins; Forecasting; Growth Substances; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Lymphokines; Metalloendopeptidases; Mice; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Phenylalanine; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Research; Signal Transduction; Thalidomide; Thiophenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
[Angiogenesis and metastasis in colorectal cancer].
Topics: Angiopoietin-1; Angiopoietin-2; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Colorectal Neoplasms; Enzyme Inhibitors; Gefitinib; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasm Metastasis; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor A | 2003 |
[Research on the antimetastatic agents].
Topics: Angiogenesis Inducing Agents; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Adhesion Molecules; Cell Movement; CSK Tyrosine-Protein Kinase; Cytokines; Drug Design; Enzyme Inhibitors; Extracellular Matrix; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Neoplasm Metastasis; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Nitriles; Platelet Aggregation Inhibitors; Protein-Tyrosine Kinases; Quinolines; Signal Transduction; src-Family Kinases | 2005 |
[Anti-angiogenesis treatment for brain tumors--present and future].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Depression, Chemical; Fibroblast Growth Factors; Glioma; Humans; Hydroxamic Acids; Metalloproteases; Neovascularization, Pathologic; Receptors, Fibroblast Growth Factor; Receptors, Vascular Endothelial Growth Factor; Retinoids; Suramin; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2005 |
[Development of anti tumor agents targeting angiogenesis].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclohexanes; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Hydroxamic Acids; Interferon-alpha; Interleukin-12; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Phenylalanine; Platelet Factor 4; Polysaccharides, Bacterial; Sesquiterpenes; Thalidomide; Thiophenes; Triazines; Triazoles; Tumor Cells, Cultured | 1997 |
Matrix metalloproteinase inhibitors.
Topics: Antineoplastic Agents; Cell Division; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Down-Regulation; Drugs, Investigational; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Hydroxamic Acids; Metalloendopeptidases; Molecular Weight; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Phenylalanine; Protease Inhibitors; Protein Kinase C; Proteins; Thiophenes; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinase-3; Tissue Inhibitor of Metalloproteinases | 1997 |
[Neovascularization and tumor development].
Topics: Angiostatins; Antibiotics, Antineoplastic; Antineoplastic Agents; Collagen; Cyclohexanes; Endostatins; Humans; Hydroxamic Acids; Interferons; Interleukin-12; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Peptide Fragments; Phenylalanine; Plasminogen; Sesquiterpenes; Thalidomide; Thiophenes | 1998 |
[Extracellular matrix degradation enzymes: important factors in liver metastasis of colorectal cancer and good targets for anticancer metastatic therapy].
Topics: Colorectal Neoplasms; Enzyme Inhibitors; Extracellular Matrix; Humans; Hydroxamic Acids; Liver Neoplasms; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Invasiveness; Neovascularization, Pathologic; Plasminogen Activators | 2001 |
10 other study(ies) available for marimastat and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Inhibition of MMPs supports amoeboid angiogenesis hampering VEGF-targeted therapies via MLC and ERK 1/2 signaling.
Topics: Amoeba; Angiogenesis Inhibitors; Animals; Endothelial Cells; Female; MAP Kinase Signaling System; Matrix Metalloproteinases; Mice; Morphogenesis; Neoplasms; Neovascularization, Pathologic; Signal Transduction; Vascular Endothelial Growth Factor A | 2023 |
Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Caseins; Cell Line, Tumor; Drug Liberation; Female; Hyaluronic Acid; Hydroxamic Acids; Mammary Neoplasms, Experimental; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, Inbred BALB C; Nanoconjugates; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Prodrugs; Protein Binding | 2018 |
MT1-MMP silencing by an shRNA-armed glioma-targeted conditionally replicative adenovirus (CRAd) improves its anti-glioma efficacy in vitro and in vivo.
Topics: Adenoviridae; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Genetic Therapy; Genetic Vectors; Glioma; Humans; Hydroxamic Acids; Interleukin-8; Male; Matrix Metalloproteinase 14; Mice; Middle Aged; Neoplasm Transplantation; Neovascularization, Pathologic; Oncolytic Virotherapy; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2015 |
In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Female; Head and Neck Neoplasms; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neovascularization, Pathologic; Protease Inhibitors; Transplantation, Heterologous; Treatment Outcome | 2009 |
An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: actions of TNP-470, marimastat and the tubulin-binding agent Ang-510.
Topics: Angiogenesis Inhibitors; Animals; Benzene Derivatives; Capillaries; Cyclohexanes; Disease Models, Animal; Endothelium, Vascular; Enzyme Inhibitors; Hydroxamic Acids; In Vitro Techniques; Mice; Neovascularization, Pathologic; Neovascularization, Physiologic; O-(Chloroacetylcarbamoyl)fumagillol; Organophosphorus Compounds; Sesquiterpenes; Tubulin Modulators | 2010 |
Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants.
Topics: Amides; Animals; Aorta, Thoracic; Cell Division; Cell Line; Drug Synergism; Enzyme Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, SCID; Microscopy, Fluorescence; Myosin-Light-Chain Phosphatase; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphoprotein Phosphatases; Phosphorylation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Pyridines; Rabbits; rho-Associated Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition.
Topics: Animals; Enzyme Inhibitors; Gelatinases; Humans; Hydroxamic Acids; Immunohistochemistry; Mice; Mice, SCID; Microcirculation; Neovascularization, Pathologic; Osmosis; Peritoneum; Platelet Endothelial Cell Adhesion Molecule-1; Stomach Neoplasms; Time Factors; Tumor Cells, Cultured | 2003 |
Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anticoagulants; Captopril; Dalteparin; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; P-Selectin; Platelet Activation; Thromboplastin; Vascular Endothelial Growth Factor A | 2005 |
Inhibitors of angiogenesis enter phase III testing.
Topics: Angiostatins; Animals; Antineoplastic Agents; Biphenyl Compounds; Clinical Trials, Phase III as Topic; Collagen; Endostatins; Endothelium, Vascular; Humans; Hydroxamic Acids; Metalloendopeptidases; Neovascularization, Pathologic; Organic Chemicals; Peptide Fragments; Phenylbutyrates; Plasminogen | 1998 |
[Therapeutic prospects of angiogenesis inhibitors in cancerology].
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Collagen; Endostatins; Humans; Hydroxamic Acids; Lung Neoplasms; Matrix Metalloproteinase Inhibitors; Mice; Neoplasms; Neoplasms, Experimental; Neovascularization, Pathologic; Peptide Fragments; Plasminogen; Protease Inhibitors; Randomized Controlled Trials as Topic | 1999 |